Literature DB >> 16373664

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2.

Robert Godal1, Ulrich Keilholz, Lutz Uharek, Anne Letsch, Anne Marie Asemissen, Antonia Busse, Il-Kang Na, Eckhard Thiel, Carmen Scheibenbogen.   

Abstract

There is considerable interest in immunotherapeutic approaches for lymphoma. The expression of proteinase inhibitor 9 (PI-9), a molecule that inactivates granzyme B, is considered an immune escape mechanism in lymphoma. Further, lymphomas frequently overexpress the antiapoptotic molecule bcl-2, which is able to inhibit perforin-dependent cytotoxic pathways. In this study, the impact of PI-9 and bcl-2 expression on the sensitivity of lymphomas to T- and natural killer (NK) cell-mediated cytotoxicity was analyzed. We found PI-9 expression in 10 of 18 lymphoma cell lines and in 9 of 14 primary lymphomas. Overexpression of bcl-2 was found in 8 of 18 cell lines and in 12 of 14 primary lymphomas. All lymphoma cells were sensitive to cytolysis by specific T cells and cytokine-activated NK cells, and no difference in sensitivity was observed with respect to PI-9 or bcl-2 expression. Cytolysis was mediated predominantly through perforin-dependent pathways despite expression of PI-9 and bcl-2. Interestingly, the majority of lymphoma cells were resistant to cytolysis by resting allogeneic NK cells. This was due to the failure of lymphomas to induce degranulation of resting NK cells. These results show that resistance to perforin-dependent pathways is not a relevant immune escape mechanism in lymphoma and therefore is unlikely to impair clinical outcome of immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373664     DOI: 10.1182/blood-2005-07-2880

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

Review 2.  Death by a thousand cuts: granzyme pathways of programmed cell death.

Authors:  Dipanjan Chowdhury; Judy Lieberman
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

3.  B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.

Authors:  Bernd Jahrsdörfer; Sue E Blackwell; James E Wooldridge; Jian Huang; Melinda W Andreski; Laura S Jacobus; Christiana M Taylor; George J Weiner
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

4.  Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade.

Authors:  Robert Godal; Veronika Bachanova; Michelle Gleason; Valarie McCullar; Gong H Yun; Sarah Cooley; Michael R Verneris; Philip B McGlave; Jeffrey S Miller
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-06       Impact factor: 5.742

5.  Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity.

Authors:  Thomas D Cunningham; Xinguo Jiang; David J Shapiro
Journal:  Cell Immunol       Date:  2007-05-08       Impact factor: 4.868

6.  Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.

Authors:  Kristopher A Sarosiek; Hovav Nechushtan; Xiaoqing Lu; Joseph D Rosenblatt; Izidore S Lossos
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

7.  GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.

Authors:  Monrat Chulanetra; Atthapan Morchang; Elias Sayour; Lamis Eldjerou; Rowan Milner; Joanne Lagmay; Matt Cascio; Brian Stover; William Slayton; Wanpen Chaicumpa; Pa-Thai Yenchitsomanus; Lung-Ji Chang
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

8.  Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.

Authors:  M Schmidt-Hieber; A Busse; B Reufi; W Knauf; E Thiel; I W Blau
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-22       Impact factor: 4.553

9.  A Novel Serpin Regulatory Mechanism: SerpinB9 IS REVERSIBLY INHIBITED BY VICINAL DISULFIDE BOND FORMATION IN THE REACTIVE CENTER LOOP.

Authors:  Matthew S J Mangan; Catherina H Bird; Dion Kaiserman; Anthony Y Matthews; Corinne Hitchen; David L Steer; Philip E Thompson; Phillip I Bird
Journal:  J Biol Chem       Date:  2015-12-15       Impact factor: 5.157

10.  Cryptococcus neoformans directly stimulates perforin production and rearms NK cells for enhanced anticryptococcal microbicidal activity.

Authors:  Kaleb J Marr; Gareth J Jones; Chunfu Zheng; Shaunna M Huston; Martina Timm-McCann; Anowara Islam; Byron M Berenger; Ling Ling Ma; Jeremy C D Wiseman; Christopher H Mody
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.